Showing papers by "Chung-Ming Hsieh published in 2010"
TL;DR: A highly efficient yeast transformation method by electroporation that enables the generation of very large and productive human antibody libraries for antibody discovery, and is now routinely making 10(9) libraries in a day for antibody engineering purposes.
Abstract: Antibody library selection by yeast display technology is an efficient and highly sensitive method to identify binders to target antigens. This powerful selection tool, however, is often hampered by the typically modest size of yeast libraries (approximately 10(7)) due to the limited yeast transformation efficiency, and the full potential of the yeast display technology for antibody discovery and engineering can only be realized if it can be coupled with a mean to generate very large yeast libraries. We describe here a yeast transformation method by electroporation that allows for the efficient generation of large antibody libraries up to 10(10) in size. Multiple components and conditions including CaCl(2), MgCl(2), sucrose, sorbitol, lithium acetate, dithiothreitol, electroporation voltage, DNA input and cell volume have been tested to identify the best combination. By applying this developed protocol, we have constructed a 1.4 x 10(10) human spleen antibody library essentially in 1 day with a transformation efficiency of 1-1.5 x 10(8) transformants/microg vector DNA. Taken together, we have developed a highly efficient yeast transformation method that enables the generation of very large and productive human antibody libraries for antibody discovery, and we are now routinely making 10(9) libraries in a day for antibody engineering purposes.
355 citations
Patent•
05 Mar 2010TL;DR: Proteins that bind IL-17 and/or IL 17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL 17 related diseases and for detecting IL 17 in cells, tissues, samples, and compositions as mentioned in this paper.
Abstract: Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.
100 citations
Patent•
27 Aug 2010TL;DR: Improved DLL4 binding proteins are described in this paper, including antibodies, CDR-grafted antibodies, human antibodies, and binding fragments thereof, proteins that bind DLL 4 with high affinity, and proteins that neutralize Dll 4 activity.
Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
48 citations
Patent•
27 Aug 2010
TL;DR: In this article, the authors concerne des proteines ameliorees se liant a DLL4, comprenant des anticorps, des anticoreps greffes sur des CDR, des anti-orps humains, and des fragments de ceux-ci se ling a Dll4.
Abstract: Cette invention concerne des proteines ameliorees se liant a DLL4, comprenant des anticorps, des anticorps greffes sur des CDR, des anticorps humains, et des fragments de ceux-ci se liant a DLL4, des proteines se liant a DLL4 a une affinite elevee, et des proteines se liant a DLL4 qui neutralisent l'activite DLL4. Les proteines se liant a DLL4 sont utiles pour traiter ou prevenir les cancers et les tumeurs et notamment, pour traiter ou prevenir l'angiogenese tumorale, et/ou d'autres maladies angiogenese-dependantes telles que la neovascularisation oculaire, ou des maladies angiogenese-independantes caracterisees par une expression ou une activite aberrante de DLL4 telles que les troubles auto-immuns comprenant la sclerose en plaques.